Kura Oncology (KURA) Other Accumulated Expenses (2015 - 2026)

Kura Oncology (KURA) has 12 years of Other Accumulated Expenses data on file, last reported at $3.6 million in Q1 2026.

• On a quarterly basis, Other Accumulated Expenses rose 3.18% year-over-year to $3.6 million in Q1 2026; TTM through Mar 2026 was $3.6 million, a 3.18% increase from a year earlier, with the FY2025 full-year figure at $3.4 million, up 25.17% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $3.6 million, up from $3.4 million in the prior quarter.
• Over the last five years, Other Accumulated Expenses for KURA reached as high as $6.3 million in Q3 2025 and fell as low as $1.3 million in Q4 2023.
• Historically, Other Accumulated Expenses has averaged $2.8 million across 5 years, with a median of $2.5 million in 2022.
• Across the five-year window, Other Accumulated Expenses plunged 46.55% in 2023 and jumped 154.36% in 2025, its largest moves.
• Year by year, Other Accumulated Expenses stood at $2.4 million in 2022, then plunged by 46.55% to $1.3 million in 2023, then surged by 108.14% to $2.7 million in 2024, then rose by 25.17% to $3.4 million in 2025, then increased by 6.1% to $3.6 million in 2026.
• Per Business Quant data, the three most recent Other Accumulated Expenses figures were $3.6 million in Q1 2026, $3.4 million in Q4 2025, and $6.3 million in Q3 2025.